FLCN and neoplasm: APC (p = 8.35e−26), TSC2 (p = 0.001), FLCN (p = 3.77e−7), and MAP2K4 (p = 0.002) were significantly more likely to be mutated in MSLN low tumor samples whereas KRAS (p = 2.58e−89), FBXW7 (p = 8.38e−16), RNF43 (p = 4.06e−10), GNAS (p = 4.36e−29), SMAD2 (p = 4.7e−6), BMPR1A (p = 1e−4), and STK11 (p = 8.61e−6) were significantly more likely to be mutated in MSLN high tumor samples (Fig. 2B).